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Abstract
Introduction: Anemia and diabetes are risk factors for short-term mortality following an acute
myocardial infarction(AMI). Anemia is more prevalent in patients with diabetes. We performed a
retrospective study to assess the impact of the combination of diabetes and anemia on post-
myocardial infarction outcomes.
Methods: Data relating to all consecutive patients hospitalized with AMI was obtained from a
population-based disease-specific registry. Patients were divided into 4 groups: diabetes and anemia
(group A, n = 716), diabetes and no anemia (group B, n = 1894), no diabetes and anemia (group C,
n = 869), and no diabetes and no anemia (group D, n = 3987). Mortality at 30 days and 31 days to
36 months were the main outcome measures.
Results: 30-day mortality was 32.3% in group A, 16.1% in group B, 21.5% in group C, 6.6% in group
D (all p < 0.001). 31-day to 36-month mortality was 47.6% in group A, 20.8% in group B, 34.3% in
group C, and 10.4% in group D (all p < 0.001). Diabetes and anemia remained independent risk
factors for mortality with odds ratios of 1.61 (1.41–1.85, p < 0.001) and 1.59 (1.38–1.85, p < 0.001)
respectively at 36 months. Cardiovascular death from 31-days to 36-months was 43.7% of deaths
in group A, 54.1% in group B, 47.0% in group C, 50.8% group D (A vs B, p < 0.05).
Interpretation: Patients with both diabetes and anemia have a significantly higher mortality than
those with either diabetes or anemia alone. Cardiovascular death remained the most likely cause
of mortality in all groups.
Introduction
Both anemia and diabetes mellitus (DM) are recognized
as strong, independent risk factors for mortality and recur-
rent ischemia after acute myocardial infarction (AMI). [1-
6] Anemia is 2–3 times more common in individuals with
DM compared to those without DM, controlling for
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glomerular filtration rates and iron stores[7]. Recent stud-
ies have shown that anemia is associated with increased
short-term mortality in patients with IHD. However, little
is known concerning the long-term survival of IHD
patients with anemia. One study suggested no difference
in long-term mortality with anemia once various con-
founding conditions were adjusted for[8]. Since anemia is
often a marker of an underlying disease, the actual causes
of death associated with a low hemoglobin level are
unknown. These patients may be dying of an associated
condition and not from cardiovascular disease. Further-
more, the outcome of acute MI patients that have both
anemia and diabetes has not been studied to date.
We undertook a study to assess the impact of anemia on
both short, and long-term morbidity and mortality in
post-AMI patients with and without DM, and to identify
the cause-specific mortality in this population.
Methods
Study setting, design and population
The Improving Cardiovascular Outcomes in Nova Scotia
(ICONS) Study, was a large prospective cohort, disease
management initiative whose rationale and methods have
been comprehensively described elsewhere[9]. As part of
this study, detailed clinical data were collected through
primary chart audit by trained abstractors at adult care
hospitals throughout the province of Nova Scotia, Canada
on all patients with AMI admitted since October 15, 1997
until December 31, 2001. Patients were divided into four
groups based on whether or not they had anemia or dia-
betes on admission. Diabetes was defined as either a pre-
vious history of diabetes or admission glucose of > 200
mg/dL based upon the 2003 Canadian Diabetes Associa-
tion clinical practice guidelines[10]. Anemia was defined
as hemoglobin < 12.0 g/dL in females and < 13.0 g/dL in
males, according to the World Health Organization crite-
ria for anemia[11].
Data elements
The data abstracted for analysis included patient demo-
graphics and clinical characteristics such as age, sex, body
mass index (BMI), blood pressure, type of AMI, smoking
status, family history of coronary heart disease, history of
previous AMI or previous congestive heart failure (CHF),
therapies during hospitalization, cardiac drugs on dis-
charge, mortality, and readmission with either re-infarc-
tion, unstable angina, CHF or AMI. Laboratory results that
were collected included mean glucose on admission,
hemoglobin on admission, lipid profile, serum creatinine
kinase, and serum creatinine. Creatinine clearance was
calculated using the Cockroft-Gault equation. Individual
cause-specific mortality was obtained from the Vital Sta-
tistics Registry of the Province of Nova Scotia via the
Department of Health, as reported through ICD-9 and
ICD-10 codes.
Outcomes of interest
These included mortality at 30 days and out to 36 months;
readmission for unstable angina, or nonfatal myocardial
infarction, or congestive heart failure; a composite of all
three morbidity endpoints; and cause of death at 30 days
and out to 36 months.
Data analysis
Demographic and clinical characteristics of the study
groups were compared using ANOVA for continuous var-
iables and chi-square tests for categorical variables. Those
data elements found to differ among the study groups in
univariate analyses at a significance level of p < 0.05 were
entered into a Cox Proportional Hazards regression
model with mortality (either within 30 days or between
31 days and 36 months of index admission) as the meas-
ure of interest. A backward elimination method was cho-
sen wherein all potential predictors were entered as a
block and removed in a stepwise fashion depending on
the relationship of each with the outcome, resulting in the
most parsimonious models representing the relationships
between the predictor and the outcome variables. For
illustrative purposes, patients were categorized into quin-
tiles of hemoglobin levels separately for each sex and a
survival curve to 36 months was plotted. All analyses were
conducted using SPSS 10.0 (Chicago, IL).
Ethics review
The original ICONS Study protocol underwent ethics
review at the Queen Elizabeth II Health Sciences Centre in
Halifax and at participating institutions across Nova Sco-
tia. The present study protocol underwent additional eth-
ics appraisal at the Queen Elizabeth II Health Sciences
Centre in Halifax.
Results
Between October 15, 1997 and December 31, 2001, 7507
patients were admitted with acute MI. Due to incomplete
information, 41 patients were excluded from the subse-
quent analysis. The remaining 7466 patients (99.5%)
were included in the study and followed for up to 36
months from their index admission. Patients were divided
into four groups on the basis of anemia and diabetes sta-
tus: group A (patients with DM and anemia [n = 716]),
group B (patients with DM but without anemia [n =
1894]), group C (patients without DM but with anemia [n
= 869]), and group D (patients without DM and without
anemia [n = 3987]).
Baseline characteristics
Table 1 describes the baseline characteristics of the study
sample. The prevalence of anemia in DM patients wasCardiovascular Diabetology 2006, 5:8 http://www.cardiab.com/content/5/1/8
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27.4% compared with 17.9% in the non-DM group (p <
0.001). Patients with anemia tended to be older in both
the diabetes (74.0 y vs. 67.8 y, p < 0.05) and non-diabetes
(76.1 y vs. 64.2 y, p < 0.05) groups. Patients with anemia
had lower creatinine clearances (group A = 39.2 mL/min,
group B = 61.4 mL/min, group C = 41.5 mL/min, group D
= 64.6 mL/min, all p < 0.001, except A and C p=ns). Most
patients with anemia had sustained a non-ST elevation MI
on admission (Group A = 72.7% and group C = 67.7%),
whereas patients without anemia were more likely to have
experienced an ST-elevation MI (Group B = 38.9% and
group D = 43.2%).
Cardiac risk factors
These are summarized in Table 2. Patients with anemia
were less likely to have family history of premature coro-
nary artery disease (group A 10.8%, group C 13.1%, group
B 19.6%, and group D 32.2%). The incidence of previous
MI (group A 32.0%, group B 26.1%, group C 27.3%, and
group D 17.9%) and CHF (group A 27.9%, group B
12.0%, group C 18.8%, and group D 4.8%) was signifi-
cantly higher in the presence of anemia, diabetes or both.
More patients with DM had a previous history of hyper-
tension (group A 63.3%, group B 61.4%, group C 51.4%,
and group D 43.7%, all between group comparisons, p <
0.001, except A vs. B, p = ns)
Outcome findings
All cause mortality was calculated separately as mortality
within 30 days of admission, and mortality from 31 days
to 36 months to reflect both short and long-term out-
come. These data are summarized in Table 3. The short-
term all-cause mortality in group A was 32.3%, group B
was 16.1%, group C was 21.5%, and group D was 6.6%
(all p < 0.001). The long-term mortality in group A was
47.6%, group B was 20.8%, group C was 34.3%, and
group D was 10.4% (all p < 0.001). In terms of morbidity,
there was no difference in the composite endpoint of
admission for non-fatal re-infarction and/or CHF and/or
or unstable angina between groups at 30 days. From 31
Table 1: Baseline Characteristics of patients presenting to hospital with MI
Group A Diabetes 
Anemia n = 716
Group B Diabetes No Anemia 
n = 1894
Group C No Diabetes Anemia 
n = 869
Group D No Diabetes No 
Anemia n = 3987
Age [years] (SD) 74.0 (11.1)bb,c,dd 67.8 (12.5)aa,cc,dd 76.1 (13.2)a,bb,dd 64.2 (13.9)aa,bb,cc
Male [%] 51.8b,c,d 58.0a,d 58.8a,d 67.7a,b,c
BMI [kg/m2] (SD) 28.2 (6.6)bb,cc 29.6 (6.2)aa,cc,dd 26.1 (5.6)aa,bb,dd 27.7 (5.1)bb,cc
Systolic BP [mmHg] (SD) 133 (34)bb,dd 146 (33))aa,cc,dd 133 (32)bb,dd 142 (29)aa,bb,cc
Diastolic BP [mmHg] (SD) 75 (17)bb,dd 85 (18))aa,cc 75 (18)bb,dd 84 (21)aa,cc
Glucose [mg/dL] (mmol/L) 252 (14.0)cc,dd 256 (14.2)cc,dd 130 (7.2)aa,bb 130 (7.2)aa,bb
Hemoglobin [g/dL] 10.83bb,cc,dd 14.44aa,cc 11.10aa,bb,dd 14.50aa,cc
Total Chol [g/dL] (mmol/L) 173 (4.47)bb,dd 191 (4.95)aa,cc,dd 174 (4.50)bb,dd 198 (5.11)aa,bb,cc
LDL [mmol/L](mg/dL) 103 (2.66)d 114 (2.96) 109 (2.82) 128 (3.30)a
HDL [mmol/L] (mg/dL) 41 (1.05) 52 (1.34) 41 (1.07) 49 (1.28)
Creatinine [µmol/L] (mg/dL) 2.0 (180)bb,cc,dd 1.2 (110)aa,cc,dd 1.7 (153)aa,bb,dd 1.1 (100)aa,bb,cc
Creatinine Clearance [mL/min] 39.2bb,dd 61.4aa,cc,dd 41.5bb,dd 64.6aa,bb,cc
Creatinine Kinase [U/L] 835 bb,dd 1072aa,cc 842bb,dd 1137aa,cc
CK-MB [U/L] 67bb,dd 61.4aa,cc,dd 41.5bb,dd 64.6aa,bb,cc
ST-elevation on ECG (%) 27.3bb,c,dd 38.9aa,cc,d 32.3a,bb,dd 43.2aa,b,cc
a signifies p < 0.05 between group A and current group. b signifies p < 0.05 group B and current group. c signifies p < 0.05 between group C and 
current group. d signifies p < 0.05 between group D and current group. Double symbol (e.g. aa) signifies p < 0.001.
Table 2: Cardiac Risk Factors
Group A Diabetes 
Anemia n = 716
Group B Diabetes No 
Anemia n = 1894
Group C No Diabetes 
Anemia n = 869
Group D No Diabetes 
No Anemia n = 3987
Family History of CAD (%) 10.8b,c 19.6a,c,d 13.1b,d 32.2a,b,c
Smoker or ex-smoker (%) 56.0b,d 63.9a,c,d 59.0b,d 69.2a,b,c
Previous Diagnosis HTN (%) 63.3cc,dd 61.4cc,dd 51.4aa,bb,dd 43.7aa,bb,cc
Previous MI (%) 32.0b,d 26.1a,d 27.3d 17.9a,b,c
Previous CHF (%) 27.9b,c,d 12.0a,c,d 18.8a,b,d 4.8a,b,c
a signifies p < 0.05 between group A and current group. b signifies p < 0.05 group B and current group. c signifies p < 0.05 between group C and 
current group. d signifies p < 0.05 between group D and current group. Double symbol (e.g. aa) signifies p < 0.001.Cardiovascular Diabetology 2006, 5:8 http://www.cardiab.com/content/5/1/8
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days to 36 months, group B had the highest number of
events, which was significant when compared with the
non-diabetic groups (group A 23.0%, group B 24.8%,
group C 20.8%, and group D 22.1%, p < 0.05 for group B
vs group C and D). When individual components of mor-
bidity were studied between 31 days and 36 months, there
were no significant differences in rates of admission for
non-fatal reinfarction. CHF admissions were highest in
Table 3: Morbidity and Mortality
Group A Diabetes 
Anemia n = 716
Group B Diabetes No 
Anemia n = 1894
Group C No Diabetes 
Anemia n = 869
Group D No Diabetes 
No Anemia n = 3987
Mortality
≤30 days 231 (32.3)bb,cc,dd 305 (16.1)aa,cc,dd 308 (21.5)aa,bb,dd 263 (6.6)aa,bb,cc
31d – 36 months (% of 30d 
survivors)
231 (47.6)bb,cc,dd 331(20.8)aa,cc,dd 192 (34.3)aa,bb,dd 387 (10.4)aa,bb,cc
Morbidity ≤30 days
Reinfarction 7 (1.0) 17 (0.9) 10 (1.2) 38 (1.0)
CHF admission 27 (3.8)b,c,dd 55 (2.9)a,dd 15 (1.7)a 57 (1.4)aa,dd
Unstable Angina (UA) 17 (2.4)b,dd 82 (4.3)a,dd 28 (3.2)d 226 (5.7)aa,bb,c
Composite end-point 
(Reinfarction, CHF, UA)
51 (7.1) 154 (8.1) 53 (6.1) 321 (8.1)
Morbidity 31 days – 36 
months
Reinfarction 24 (3.4) 55 (2.9) 18 (2.1) 97 (2.4)
CHF admission 86 (12.0)bb,c,dd 126 (6.7)aa,cc,dd 71 (8.2)a,bb,dd 116 (2.9)aa,bb,cc
Unstable Angina (UA) 55 (7.7)bb,c,dd 288 (15.2)aa,c,dd 92 (10.6)a,b,dd 668 (16.8)aa,bb,cc
Composite end-point 
(Reinfarction, CHF, UA)
165 (23.0) 469 (24.8)c,d 181 (20.8)b 881 (22.1)b
a signifies p < 0.05 between group A and current group. b signifies p < 0.05 group B and current group. c signifies p < 0.05 between group C and 
current group. d signifies p < 0.05 between group D and current group. Double symbol (e.g. aa) signifies p < 0.001. Percentages do not always add 
to total due to rounding.
Table 4: Adjusted Odds Ratios Using a Backward Elimination Model for Mortality
Mortality ≤30 days Mortality 31d – 36 m
Adjusted OR p-value 95% CI Adjusted OR p-value 95% CI
Comorbid 
conditions
Diabetes 1.45 <0.001 1.20 – 1.76 1.61 <0.001 1.41 – 1.85
Anemia 1.59 <0.001 1.38 – 1.85
Age (per year) 1.01 0.01 1.00 – 1.02 1.03 <0.001 1.03 – 1.04
Smoking 1.23 0.007 1.06 – 1.42
Previous MI 1.55 <0.001 1.34 – 1.79
On Admission
STEMI 1.26 0.02 1.04 – 1.53
Systolic BP >140 
mmHg
0.68 <0.001 0.56 – 0.83




0.99 0.007 0.99 – 1.00 0.98 <0.001 0.98 – 0.99
Therapy during 
hospitalization
CABG 0.59 0.02 0.39 – 0.89 0.58 <0.001 0.46 – 0.72
PCI 0.52 <0.001 0.41 – 0.66
Thrombolysis 0.58 <0.001 0.48 – 0.70
Medication on 
discharge
B-blocker N/A 0.64 <0.001 0.54 – 0.74
ASA N/A 0.70 <0.001 0.60 – 0.82
Statin N/A 0.79 0.002 0.68 – 0.91Cardiovascular Diabetology 2006, 5:8 http://www.cardiab.com/content/5/1/8
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patients with diabetes and anemia (group A 12.0%, group
B 6.7%, group C 8.2%, group D 2.9%, all p < 0.001, except
A vs C p < 0.05). For unstable angina, the patients with
anemia had higher rates of readmission (group A 7.7%,
group B 15.2%, group C 10.6%, group D 16.8%, all p <
0.001, except A vs. C and B vs. C, p < 0.05).
Table 4 summarizes the final step in each of the two
regression models predicting mortality. Only variables
having a significant relationship with the outcome, after
controlling for the influence of the other covariates, were
retained in the models. Diabetes was an independent risk
factor in both short and long-term mortality (30-day OR
1.45 [CI = 1.20–1.76], 36-month OR 1.61 [CI = 1.41–
1.85], both p <0.001). Short-term mortality was not
directly influenced by anemia once other variables were
included. However, anemia on admission remained inde-
pendently associated with mortality in the long-term (OR
1.59, CI = 1.38 – 1.85). Figure 1 shows the long-term sur-
vival rate of patients according to their DM and anemia
status after controlling for the covariates listed in Table 4.
The overall mortality in each group containing patients
with anemia was higher than in the corresponding non-
anemic groups. Similarly, there was a drop in survival to
36 months concomitant with a low hemoglobin level at
admission (Fig 2 and 3).
Cause of death
The cause-specific mortality data are summarized in table
5. At 30 days, the overwhelming majority of patient
deaths were due to cardiovascular disease (group A
73.2%, group B 82.6%, group C 73.8%, and group D
85.9%). By 36 months, cardiovascular death remained the
most common cause of mortality overall (group A 43.7%,
group B 54.1%, group C 47.0%, and group D 50.8%,
group A to B p < 0.05) but between 50% and 60% of
deaths were now due to competing etiologies across
groups. Patients in group C had a higher rate of death due
to cancer at 30 days (7.0% vs group A 1.7%, group B 0.0%,
group D 0.8%, all p < 0.05). However, at 36 months, this
difference lost some significance. Although there was a
higher 30-day mortality due to gastrointestinal causes in
the two anemia groups, (group A 3.5% and group C 2.7%
vs. groups B 0.3% and D 0.8%) no difference in mortality
due to gastrointestinal disease was seen at 36 months.
Discussion
The current study extends previous knowledge about both
the short and long term risk of death in patients who
present with an AMI. The purpose of this study was two-
fold. First, we wanted to assess the impact of anemia and
DM together on outcomes of patients with AMI. Second,
we sought to identify cause-specific mortality in patients
with anemia. Though our results confirm anemia as an
independent risk factor for mortality in the post-MI pop-
ulation, they differ significantly from other published
Unadjusted female survival by hemoglobin quintile Figure 2
Unadjusted female survival by hemoglobin quintile. Survival rates after adjusting for covariates Figure 1
Survival rates after adjusting for covariates.Cardiovascular Diabetology 2006, 5:8 http://www.cardiab.com/content/5/1/8
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data[1,2,12]. While recent reports have shown that ane-
mia is an independent predictor for short-term mortal-
ity[1,2], our data suggest that low hemoglobin is a risk
factor for long-term mortality only. One possible explana-
tion for this discordance may be the differences in both
study design and the definition of anemia. For instance, a
previous study of elderly medicare patients reported a
negative correlation between 30-day mortality and pro-
gressively lower hematocrit levels, but this was unadjusted
mortality[12]. Similarly, Lipšic et al. found higher
adjusted 30-day mortality when a hemoglobin of 100 g/L
was used as criteria for anemia, but did not correct for as
many potential confounders as we did[2]. Furthermore,
Sabatine et al., in a post-hoc analysis of the TIMI trials, did
not find an increase in cardiovascular mortality, myocar-
dial infarction, or recurrent ischemia in NSTEMI patients
until hemoglobin values dropped below 110 g/L[1]. In
our study, we defined anemia as a hemoglobin <120 g/L
in females and <130 g/L in males. When analyzed by
quintile, the impact of anemia on survival was more pro-
nounced in the lowest quintile of hemoglobin for both
men and women regardless of their DM status. Our study
may have not shown a difference in short-term mortality
because it examined any degree of anemia. Milder cases of
anemia may have had minimal impact on short-term out-
come and could therefore have masked any potential
mortality risk in patients with more severe anemia.
Another possible explanation for this disparity may have
to do with the differences in transfusion rates among
groups. A recent report suggests a potential detrimental
effect of blood transfusion in acute coronary syn-
drome[13]. We did not have any information about the
frequency of blood transfusion in these patients.
In our study, mortality at 36-months was significantly
increased in both anemia groups. The combination of dia-
betes and anemia was associated with a significant risk of
death over 36 months, with almost 65% of patients dying
by 36 months. The reasons for the increased long-term
mortality may be multifactorial. Anemia has been shown
to be well tolerated in the normal functioning heart[14].
The increase in cardiac output via a higher heart rate,
larger stroke volume, and decrease in blood viscosity com-
pensates for the decreased oxygen carrying capacity of the
blood. [15-17] These compensatory mechanisms are
mediated partially through activation of the sympathetic
nervous system, which has been shown to be deleterious
in coronary artery disease. [18-20] In animal studies, ane-
mia in the presence of a fixed coronary artery stenosis
reduces the ability of the heart to increase cardiac output
and thereby results in left ventricle dysfunction[21,22].
Exacerbation of left ventricular dysfunction or ischemia
by anemia in the post-MI patient may be partially respon-
sible for the excess long-term mortality in this population.
Anemia could result from a variety of diseases, which may
have an impact on the overall survival. Therefore, to
address this issue we also examined cause-specific mortal-
ity. In our study, the majority of patients in both anemia
and non-anemia groups died of cardiovascular disease
both within 30 days and at 36 months. The rate of cardi-
ovascular death was only different among patients with
diabetes, with and without anemia. Unfortunately, a sig-
nificant number of patients in the DM groups (14.7%
with anemia and 10.9% without anemia) had their cause
of death listed as 'diabetes'. This may have misclassified
many deaths as non-cardiac, when in fact they may well
have died from cardiovascular disease. More importantly,
patients with anemia did not have significantly higher
rates of death from non-cardiac causes such as cancer or
hemorrhage, indicating that not only were mortality rates
higher in both anemia groups, but the majority of people
still died of cardiovascular disease.
We found no between group difference in the composite
morbidity endpoint at 30 days, which may have been
related to the high mortality among patients with both
DM and anemia. Clearly, patients who died during their
index hospitalization could not have been expected to
have later events. When we excluded patients dying within
30 days, there was a trend towards more readmissions for
CHF, unstable angina, and recurrent nonfatal MI in the
DM and anemia group. CHF admissions and unstable
angina admissions tended to be inversely related,
Unadjusted male Survival by hemoglobin quintile Figure 3
Unadjusted male Survival by hemoglobin quintile.Cardiovascular Diabetology 2006, 5:8 http://www.cardiab.com/content/5/1/8
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although the only group with a higher incidence of
readmission for CHF than unstable angina was that with
both DM and anemia. Silent ischemia and CHF are cer-
tainly well recognized complications of DM and anemia
respectively. [23-28]
This is a retrospective observational study with all the
inherent limitations of such a design. Unrecorded comor-
bidities, treatment decisions, or interventions such as
blood transfusions may have influenced mortality rates
within the four groups, although we corrected for an
extensive list of potential confounders with the exception
of transfusions. We could only identify readmissions for
those conditions listed and other outcome differences
may have existed between study cohorts. However, CHF,
unstable angina and nonfatal recurrent MI are the most
common reasons for readmission following AMI. We
were not able to identify cause of death in 1.7% of
patients, although classification issues in such a small per-
centage of all study patients are unlikely to have systemat-
ically biased our results in any direction. By contrast,
conditions that are not generally understood to lead
directly to death (e.g. diabetes and hypercholesterolemia)
were listed as a primary cause of death in a measurable
number of patients. If anything, this would only be
expected to strengthen the association between anemia
and cardiac disease, as these conditions typically lead to
death through their contributions to cardiovascular dis-
ease. Although the accuracy of coding of the Vital Statistics
Registry of the province of Nova Scotia has not been pub-
lished, the Canadian registries, when compared to other
vital statistics registries, have been reported to have 100%
completeness, and a low rate of coding to ill-defined
causes of death (7%)[29].
Strengths of our study include the fact that data were
obtained on a large and contemporaneous, population-
based cohort of consecutively hospitalized patients across
an entire health care system. Furthermore, the data col-
lected were rich in clinical detail. Finally, we had access
not only to all-cause mortality but also on cause-specific
death courtesy of our ability to link to the provincial Vital
Statistics Registry.
Conclusion
In a large consecutive and unselected population of
patients hospitalized with an AMI, we have confirmed
diabetes as being a strong independent risk factor for both
Table 5: Mortality at 30 Days and 36 Months by Cause of Death
Cause of death within 
30 days
Group A Diabetes 
Anemia (% deaths 
<=30d)
Group B Diabetes No 
anemic (% deaths 
<=30d)
Group C No diabetes 
Anemia (% deaths 
<=30d)
Group D No diabetes 
No anemia (% deaths 
<=30d)
Cancer 4 (1.7)c 0 (0.0)b 13 (7.0)a,dd 2 (0.8)cc
Cardio 169 (73.2)b,dd 252 (82.6)a,c 138 (73.8)b,d 226 (85.9)aa,c
Stroke 3 (1.3) 10 (3.3) 4 (2.1) 6 (2.3)
Diabetes 18 (7.8)cc,dd 17 (7.4)cc,dd 0 (0.0) 0 (0.0)
G I cause 8 (3.5)bb 1 (0.3)aa,cc 5 (2.7)bb 2 (0.8)
Infection 5 (2.2) 8 (2.6) 3 (1.6) 9 (3.4)
Renal 4 (1.7) 3 (1.0) 5 (2.7) 2 (0.8)
Lung Disease 3 (1.3) 3 (1.0) 6 (3.2) 7 (2.7)
Other 16 (6.9) 11 (3.6) 12 (6.4) 8 (3.0)
Unknown 1 (0.4) 0 (0.0) 1 (0.5) 1 (0.4)
Total 231 305 187 263
Cause of death 31 days 
to 36 months
(% deaths 30 days – 36 months)
Cancer 29 (12.6) 32 (9.7)c 42 (17.9)b 56 (14.5)
Cardio 101 (43.7)b 179 (54.1)a 110 (47.0) 196 (50.8)
Stroke 5 (2.2) 18 (5.4) 13 (5.6) 23 (6.0)
Diabetes 34 (14.7)cc,dd 36 (10.9)cc,dd 1 (0.4)aa,bb 3 (0.8)aa,bb
G I cause 10 (4.3) 8 (2.4) 7 (3.0) 9 (2.3)
Infection 12 (5.2)bb 11 (3.3)aa 10 (4.3) 11 (2.8)
Renal 10(4.3) 4 (1.2) 10 (4.3) 10 (2.6)
Lung Disease 9 (3.9) 17 (5.1) 9 (3.8) 25 (6.5)
Other 13 (5.6)c 18 (5.4)c,d 29 (12.4)a,b 38 (9.8)b
Unknown 8 (3.5) 8 (2.4) 3 (1.3) 15 (3.9)
Total 231 331 234 386
a signifies p < 0.05 between group A and current group. b signifies p < 0.05 group B and current group. c signifies p < 0.05 between group C and 
current group. d signifies p < 0.05 between group D and current group. Double symbol (e.g. aa) signifies p < 0.001.Cardiovascular Diabetology 2006, 5:8 http://www.cardiab.com/content/5/1/8
Page 8 of 9
(page number not for citation purposes)
short and long-term mortality. The results of our study
suggest that anemia, when considered as a dichotomous
variable by analogy to diabetes, is not an independent risk
factor for 30-day mortality; however, it is associated with
reduced survival over the longer term and, moreover, the
greater the degree of anemia the higher the mortality rate
out to 36 months. To our knowledge, this is the first study
showing that any degree of anemia has an independent
adverse effect on long-term mortality post-myocardial inf-
arction. The combination of diabetes and anemia is par-
ticularly unfavorable as 65% of patients in this group had
died at 36 months. We have also found that the primary
cause of death in patients with anemia is cardiovascular
disease and not other conditions such as cancer, hemor-
rhage, or renal failure. Further research is now needed to
examine whether correction of anemia is a means of
reducing long-term mortality in affected patients hospital-
ized with an AMI.
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